#USA #Dallas #Nanoscope #retinitis pigmentosa #MOGENRY

Advancements in Vision Restoration: Nanoscope Therapeutics at Euretina 2026

Nanoscope Therapeutics, a pioneering biotechnology firm, is set to make significant contributions to the field of ophthalmology at the upcoming 26th Euretina Congress. Scheduled for October 1-4, 2026, in Vienna, the congress will feature groundbreaking data on the treatment of macular degeneration and retinitis pigmentosa. Nanoscope is particularly known for its innovative optogenetic therapy using sonpiretigene isteparvovec (MOGENRY®).

Dr. Jordi Mones, MD, PhD, will lead the presentation of the first direct-to-Phase 2 randomized controlled trial data, a significant advancement for those suffering from macular degeneration. This trial marks a pivotal moment in the potential to restore vision in patients with this debilitating condition. Additionally, Dr. Benjamin Bakall, MD, PhD, will present results from the REMAIN extension study, showcasing four years of data that illustrates lasting vision improvement in patients treated with MCO-010 for retinitis pigmentosa.

The leading figures of Nanoscope Therapeutics, including Dr. Samarendra Mohanty, Co-Founder and Chief Scientific Officer, will also deliver insights at the Retina Forum 2026 on September 30, 2026. Dr. Mohanty's company presentation will encapsulate the firm's vision and the groundbreaking nature of their therapies. Moreover, Dr. Samuel Barone, Chief Medical Officer, will participate in a vital panel discussing geographic atrophy and intermediate age-related macular degeneration (AMD).

Presentation Highlights

Ophthalmology Futures Forums: Retina Forum 2026

• - Company Presentation: Dr. Samarendra Mohanty, PhD
• - Date & Time: Wednesday, September 30, 2026, 17:50 PM CEST
• - Location: Imperial Riding School, Vienna

Panel Discussion:

• - Topic: Geographic Atrophy and Intermediate AMD Therapeutics
• - Panelist: Dr. Samuel Barone, MD
• - Date & Time: Wednesday, September 30, 2026, 18:20 PM CEST
• - Location: Imperial Riding School, Vienna

26th Euretina Congress Presentation:

• - Title: Vision Improvement in Macular Degeneration with Sonpiretigene Isteparvovec
• - Presenter: Dr. Jordi Mones, MD, PhD
• - Date & Time: Sunday, October 4, 2026, 10:51 AM CEST
• - Session: Free Paper 42 – AMD/CS

Poster Presentation:

• - Topic: Lasting Vision Improvement with MCO-010 in Retinitis Pigmentosa
• - Presenter: Dr. Benjamin Bakall, MD, PhD
• - Date: Thursday, October 1, 2026
• - Location: Poster Hub

These presentations at the Euretina Congress are critical for spotlighting Nanoscope's optogenetic pipeline. Their research reveals not just the direct-to-Phase 2 randomized controlled trial of sonpiretigene isteparvovec for macular degeneration, but also consolidates the efficacy data from the RESTORE Phase 2b/3 clinical trial concerning retinitis pigmentosa, underlining a comprehensive approach to treating retinal degeneration.

About MOGENRY®

MOGENRY® (sonpiretigene isteparvovec; MCO-010) represents a novel optogenetic gene therapy. It is designed to enhance light sensitivity in surviving retinal cells, thereby leveraging residual visual pathways in those who have experienced photoreceptor loss. Nanoscope’s technology is unique, as it circumvents the need for genetic testing or invasive surgical methods. This therapy aims to restore vision in individuals afflicted with retinal degenerative diseases and is poised to change the standard of care.

Nanoscope Therapeutics' commitment to advancing vision-restoring therapies is reflected in their response to the FDA, which has accepted their Biologics License Application (BLA) for MOGENRY®. If approved, this one-time, in-office injection could dramatically alter the treatment landscape for patients with retinitis pigmentosa.

Conclusion

With exciting presentations scheduled and the promising potential of MOGENRY®, Nanoscope Therapeutics continues to cement its position as a leader in the field of ophthalmological therapeutics. Stakeholders, researchers, and patients alike are keenly anticipating the results that will emerge from the Euretina Congress 2026, as the future of vision restoration looks increasingly bright.